Safety and Activity of the Once Daily Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Drug Category : Array
Conference Category : Array
Lead Author : Cheah C, et al.
Published Date : 12/06/2020
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2020/06/Final-EHA-TG-1701-Phase-1-Poster.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top